TPG Group Holdings SBS Advisors Inc. continued to hold its position in Alder Biopharmaceuticals Inc (NASDAQ:ALDR) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,238,533 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. TPG Group Holdings SBS Advisors Inc. owned about 1.83% of Alder Biopharmaceuticals worth $14,181,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Bank of Montreal Can lifted its stake in Alder Biopharmaceuticals by 3,047.2% in the 1st quarter. Bank of Montreal Can now owns 5,602 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 5,424 shares in the last quarter. Legal & General Group Plc boosted its holdings in Alder Biopharmaceuticals by 2.6% in the 2nd quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 400 shares during the period. SG Americas Securities LLC boosted its holdings in Alder Biopharmaceuticals by 109.4% in the 2nd quarter. SG Americas Securities LLC now owns 15,580 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 8,140 shares during the period. Stifel Financial Corp purchased a new position in shares of Alder Biopharmaceuticals during the 1st quarter valued at $206,000. Finally, Voya Investment Management LLC grew its position in shares of Alder Biopharmaceuticals by 8.4% during the 2nd quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 1,734 shares in the last quarter. 76.16% of the stock is currently owned by institutional investors and hedge funds.

ALDR has been the topic of several research analyst reports. ValuEngine raised shares of Alder Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, June 20th. Leerink Swann reiterated an “outperform” rating and issued a $32.00 price objective on shares of Alder Biopharmaceuticals in a research report on Monday, June 12th. Needham & Company LLC reissued a “buy” rating and set a $36.00 price objective on shares of Alder Biopharmaceuticals in a research note on Friday, June 9th. Credit Suisse Group lowered Alder Biopharmaceuticals from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $30.00 to $17.00 in a research note on Wednesday, June 28th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $47.00 target price on shares of Alder Biopharmaceuticals in a research report on Wednesday, June 28th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. Alder Biopharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $28.69.

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) traded up 0.81% on Tuesday, reaching $12.40. The company had a trading volume of 631,590 shares. The stock’s 50 day moving average price is $10.06 and its 200-day moving average price is $14.98. Alder Biopharmaceuticals Inc has a 12-month low of $8.60 and a 12-month high of $34.30. The stock’s market capitalization is $839.64 million.

Alder Biopharmaceuticals (NASDAQ:ALDR) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.67) by $0.19. Alder Biopharmaceuticals had a negative return on equity of 118.04% and a negative net margin of 10,926.65%. The company had revenue of $0.68 million for the quarter. During the same period last year, the business posted ($0.79) EPS. The firm’s revenue for the quarter was up 518.2% compared to the same quarter last year. Equities analysts expect that Alder Biopharmaceuticals Inc will post ($5.60) earnings per share for the current fiscal year.

In other Alder Biopharmaceuticals news, Director Stephen M. Dow purchased 25,000 shares of the company’s stock in a transaction on Tuesday, July 18th. The stock was acquired at an average cost of $10.00 per share, for a total transaction of $250,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 10.60% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “TPG Group Holdings SBS Advisors Inc. Holds Position in Alder Biopharmaceuticals Inc (ALDR)” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/tpg-group-holdings-sbs-advisors-inc-holds-position-in-alder-biopharmaceuticals-inc-aldr/1605769.html.

Alder Biopharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Want to see what other hedge funds are holding ALDR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alder Biopharmaceuticals Inc (NASDAQ:ALDR).

Institutional Ownership by Quarter for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.